Register for our free email digests:
Eli Lilly & Co.
www.lilly.com
Latest From Eli Lilly & Co.
Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US
US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.
What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot
China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.
ESMO Preview: Five Key Oncology Battlegrounds To Watch
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
-
Eli Lilly & Co.
- Alnara Pharmaceuticals Inc.
- Applied Molecular Evolution Inc.
- Armo BioSciences Inc.
- AurKa Pharma Inc.
- Avid Radiopharmaceuticals Inc.
- Chorus
- Chugai Lilly Clinical Research Co. Ltd.
- CoLucid Pharmaceuticals Inc.
- Eli Lilly & Co. (India) Pvt. Ltd.
- Eli Lilly Canada Inc.
- Eli Lilly Deutschland GMBH
- Eli Lilly Japan
- Eli Lilly Ranbaxy Ltd.
- Eli Lilly Suzhou Pharmaceutical Group Co. Ltd.
- Hypnion Inc.
- Icos Corp.
- ImClone Systems Inc.
- InnoCentive LLC
- Lilly Research Centre Ltd.
- Lilly Research Laboratories
- Loxo Oncology Inc.
- Medical Devices & Diagnostics
- Pacific Biotech Inc.
- SGX Pharmaceuticals Inc.
- Senior Management
-
David Ricks, CEO
Joshua L Smiley, SVP, CFO
Daniel M Skovronsky, MD, PhD, SVP, CSO - Contact Info
-
Eli Lilly & Co.
Phone: (317) 276-2000
Lilly Corporate Ctr.
Indianapolis, IN 46285
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice